Join Now!      Login

Whole Person Wellness Program Wellness Model
Skip Navigation Links
Health Centers
Key Services
America's Worst Enemy?
What is the leading cause of death in the United States?
Auto Accidents
Heart Disease
Perscription Meds

 What Doctors Don't Tell You: Drug of the Month: Relenza 
What Doctors Don't Tell You © (Volume 12, Issue 1)
It's one thing to get a drug approved for use it's quite another for the National Health Service to agree to adopt it.

GlaxoWellcome found this out to its cost after it developed Relenza (zana-mivir), the first drug for treating influenza.The stumbling block proved to be the National Institute for Clinical Excellence (NICE), which assesses for the NHS the effectiveness and cost effectiveness of drugs and treatments.

It found the drug wanting on both counts when it reviewed it in October, 1999. The Institute felt that there was not enough research to suggest that 'at risk' patients people aged over 65 years or with an existing condition that might make influenza a more severe problem would benefit from the drug.

Separately, the US Food and Drug Administration (FDA) also noted that wheezing had occurred in some patients with mild or moderate asthma after taking the drug.

At �24 for a five day course of treatment, the drug would cost the NHS up to �15 million a year if there was a 'flu epidemic.

Thirteen months later and NICE now says the drug can be prescribed to people at risk.

NICE says that further analysis suggests that the drug reduces symptoms among the 'at risk' group by 1.2 days and that, overall, it reduces the risk of complications by 6 per cent.

But there is one important dissenting voice. The Drug and Therapeutics Bulletin, whose editor Professor Joe Collier was part of the NICE committee that assessed zanamivir, believes a wrong decision has been made.

The Bulletin maintains that the study is flawed, and does not focus on 'at risk' patients as NICE believes. Even if it did, the fact that it reduces the duration of symptoms by one day is hardly

compelling, and nobody has tested the drug against over the counter remedies such as paracetamol and ibuprofen.

NICE also does not touch on the increased risk of bronchospasm, particularly among patients with asthma or chronic pulmonary disease.

All of which leaves the health professional with a dilemma to be cautious or NICE.

 Comments Add your comment 

 About The Author
What Doctors Don't Tell You What Doctors Don’t Tell You is one of the few publications in the world that can justifiably claim to solve people's health problems - and even save lives. Our monthly newsletter gives you the facts you won't......more
 From Our Friends
Popular & Related Products
Popular & Featured Events
Wellness Inventory Certification Training
     April 3-July 3, 2018
     Los Angeles, CA USA
2018 National Wellness Conference
     June 18-20, 2018
     St. Paul, MN USA
Additional Calendar Links
Dimensions of Wellness
Wellness, Finding Meaning, dimension!

Home       Wellness       Health A-Z       Alternative Therapies       Wellness Inventory       Wellness Center
Healthy Kitchen       Healthy Woman       Healthy Man       Healthy Child       Healthy Aging       Nutrition Center       Fitness Center
Discount Lab Tests      First Aid      Global Health Calendar      Privacy Policy     Contact Us
Disclaimer: The information provided on HealthWorld Online is for educational purposes only and IS NOT intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek professional medical advice from your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.
Are you ready to embark on a personal wellness journey with our whole person approach?
Learn More/Subscribe
Are you looking to create or enhance a culture of wellness in your organization?
Learn More
Do you want to become a wellness coach?
Learn More
Free Webinar